Comparison · NCT00071799-e83d4998
Azacitidine vs Conventional Care: Number of Participants Who Died
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Azacitidine vs Conventional Care: Number of Participants Who Died. Trial comparisons, record NCT00071799-e83d4998. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00071799-e83d4998
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.458 | 0.387 | 0.531 | wilson | |
| Risk in group 2 | 0.631 | 0.559 | 0.699 | wilson | |
| Risk difference, group 1 minus group 2 | -0.173 | -0.271 | -0.0701 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.726 | 0.597 | 0.882 | log | |
| Odds ratio, group 1 over group 2 | 0.494 | 0.324 | 0.753 | log | |
| Number needed to treat, for one fewer participant with the outcome on Azacitidine than on Conventional Care | 5.77 | 3.69 | 14.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Azacitidine | Azacitidine, 75 mg/m\^2/day given by subcutaneous injection for 7 days of every 28 day cycle, plus best supportive care. | 82 | 179 | OG000 |
| Group 2 | Conventional Care | Physician choice of low dose cytarabine, standard chemotherapy, or best supportive care (consisting of blood products, growth factors, antibiotics) | 113 | 179 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Who Died
- Description
- Count of participants who died during the study
- Time frame
- 42 months
- Population
- Intent to treat population
Source ClinicalTrials.gov
Trial
- Title
- A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
- NCT number
- NCT00071799
- Phases
- PHASE3
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Azacitidine, Physician Choice
- Lead sponsor
- Celgene
- Results first posted
- 2010-07-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00071799?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00071799-e83d4998